Marinus Pharmaceuticals (NASDAQ:MRNS – Get Rating) had its price target lowered by SVB Leerink from $27.00 to $23.00 in a research report sent to investors on Monday, Benzinga reports. SVB Leerink currently has an outperform rating on the biopharmaceutical company's stock. SVB Leerink also issued estimates for Marinus Pharmaceuticals' FY2023 earnings at ($3.25) EPS, FY2024 earnings at ($2.50) EPS, FY2025 earnings at ($1.50) EPS and FY2026 earnings at $1.10 EPS.
Several other research firms have also commented on MRNS. Robert W. Baird lowered their price target on shares of Marinus Pharmaceuticals from $32.00 to $24.00 and set an outperform rating on the stock in a research report on Wednesday, November 9th. Royal Bank of Canada started coverage on shares of Marinus Pharmaceuticals in a research report on Friday, January 20th. They issued an outperform rating and a $23.00 price target on the stock. StockNews.com upgraded shares of Marinus Pharmaceuticals from a sell rating to a hold rating in a research report on Monday, November 14th. Finally, HC Wainwright reiterated a buy rating and issued a $27.00 price target on shares of Marinus Pharmaceuticals in a research report on Friday, January 6th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, Marinus Pharmaceuticals has a consensus rating of Moderate Buy and an average price target of $28.13.
Get
Marinus Pharmaceuticals alerts:
Marinus Pharmaceuticals Trading Down 0.3 %
Shares of Marinus Pharmaceuticals stock opened at $5.94 on Monday. Marinus Pharmaceuticals has a 12-month low of $3.46 and a 12-month high of $12.37. The company has a current ratio of 8.41, a quick ratio of 8.40 and a debt-to-equity ratio of 0.91. The stock has a market cap of $220.95 million, a PE ratio of -12.91 and a beta of 1.10. The company has a 50-day moving average of $4.49 and a two-hundred day moving average of $5.47.
Marinus Pharmaceuticals (NASDAQ:MRNS – Get Rating) last issued its earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.25 by ($0.60). Marinus Pharmaceuticals had a negative net
margin of 77.96% and a negative return on equity of 244.60%. The company had revenue of $2.34 million during the quarter, compared to analysts' expectations of $28.56 million. On average, research analysts anticipate that Marinus Pharmaceuticals will post -2.88 EPS for the current fiscal year.
Institutional Investors Weigh In On Marinus Pharmaceuticals
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its position in shares of Marinus Pharmaceuticals by 1.0% in the 3rd quarter. Vanguard Group Inc. now owns 1,691,370 shares of the biopharmaceutical company's stock worth $11,248,000 after purchasing an additional 16,812 shares during the last quarter. BlackRock Inc. boosted its holdings in shares of Marinus Pharmaceuticals by 1.9% in the 3rd quarter. BlackRock Inc. now owns 959,198 shares of the biopharmaceutical company's stock valued at $6,379,000 after buying an additional 17,887 shares during the period. Delphia USA Inc. acquired a new position in shares of Marinus Pharmaceuticals in the 3rd quarter valued at about $86,000. Renaissance Technologies LLC boosted its holdings in shares of Marinus Pharmaceuticals by 23.2% in the 3rd quarter. Renaissance Technologies LLC now owns 193,325 shares of the biopharmaceutical company's stock valued at $1,286,000 after buying an additional 36,425 shares during the period. Finally, Assenagon Asset Management S.A. boosted its holdings in shares of Marinus Pharmaceuticals by 392.8% in the 3rd quarter. Assenagon Asset Management S.A. now owns 527,925 shares of the biopharmaceutical company's stock valued at $3,511,000 after buying an additional 420,802 shares during the period. Institutional investors own 86.88% of the company's stock.
About Marinus Pharmaceuticals
(Get Rating)
Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.
Featured Articles
- Get a free copy of the StockNews.com research report on Marinus Pharmaceuticals (MRNS)
- Chevron Delights Shareholders with $75 Billion in Share Buybacks
- The Future Of E-Commerce: Analysis And New Data
- Levi Strauss Is A Good Fit For Income Investors
- 3 Small Caps That Have Big Upside
- Mullen Automotive: The Good News, The Bad And The Ugly Outlook
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
